BLASINGLE-USEVIAL1 Generic Approved
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
BOTOX (onabotulinumtoxina) by AbbVie is acetylcholine release inhibitors [moa]. Approved for acetylcholine release inhibitor [epc]. First approved in 1991.
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BOTOX (onabotulinumtoxinA) is a neurotoxin-based biologic that inhibits acetylcholine release at the neuromuscular junction, approved for multiple therapeutic and cosmetic indications. It treats conditions ranging from chronic migraine and muscle spasticity to wrinkles and hyperhidrosis by paralyzing targeted muscles. The drug is administered via intramuscular injection in single-use vials.
$0.112BPart D
LOE ApproachingBOTOX is in late-stage lifecycle with mounting competitive pressure (30% intensity), signaling defensive positioning and potential team restructuring as exclusivity approaches.
Mechanism of Action
Acetylcholine Release Inhibitors
Pharmacologic Class:
Acetylcholine Release Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines
Started Aug 2026
120 enrolled
Glabellar Lines
The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
Started Jul 2025
8 enrolled
Atopic Dermatitis (AD)
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)
Started Feb 2025
132 enrolled
Glabellar Lines
A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants
Started Jan 2025
150 enrolled
Forehead Lines
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products
Started Jan 2025
130 enrolled
Facial Contouring
Worked on BOTOX at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.